Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20080889
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
MIRD Pamphlet No 22 (abridged): radiobiology and dosimetry of alpha-particle
emitters for targeted radionuclide therapy
#MMPMID20080889
Sgouros G
; Roeske JC
; McDevitt MR
; Palm S
; Allen BJ
; Fisher DR
; Brill AB
; Song H
; Howell RW
; Akabani G
; Bolch WE
; Brill AB
; Fisher DR
; Howell RW
; Meredith RF
; Sgouros G
; Wessels BW
; Zanzonico PB
J Nucl Med
2010[Feb]; 51
(2
): 311-28
PMID20080889
show ga
The potential of alpha-particle emitters to treat cancer has been recognized
since the early 1900s. Advances in the targeted delivery of radionuclides and
radionuclide conjugation chemistry, and the increased availability of
alpha-emitters appropriate for clinical use, have recently led to patient trials
of radiopharmaceuticals labeled with alpha-particle emitters. Although
alpha-emitters have been studied for many decades, their current use in humans
for targeted therapy is an important milestone. The objective of this work is to
review those aspects of the field that are pertinent to targeted alpha-particle
emitter therapy and to provide guidance and recommendations for human
alpha-particle emitter dosimetry.
|Alpha Particles/adverse effects/*therapeutic use
[MESH]
|Cell Death/radiation effects
[MESH]
|Cell Survival/radiation effects
[MESH]
|Clinical Trials as Topic
[MESH]
|Dose-Response Relationship, Radiation
[MESH]
|Female
[MESH]
|Humans
[MESH]
|Male
[MESH]
|Neoplasms, Radiation-Induced/etiology
[MESH]
|Neoplasms/*radiotherapy
[MESH]
|Pamphlets
[MESH]
|Radiation-Protective Agents/therapeutic use
[MESH]
|Radiobiology
[MESH]
|Radioisotopes/adverse effects/*therapeutic use
[MESH]
free
free
free
